ArticleMolecular oncology2022
Blood DNA methylation profiles improve breast cancer prediction.
Article in Molecular oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Epigenetic Ageing and Breast Cancer Risk: A Systematic Review.Cancer medicine · 2024Pooled it
- Methylation-based markers of aging and lifestyle-related factors and risk of breast cancer: a pooled analysis of four prospective studies.Breast cancer research : BCR · 2022Pooled it
- Integrating DNA methylation biomarkers for breast cancer risk prediction using artificial intelligence.Scientific reports · 2026Article
- Blood DNA methylation and breast cancer risk: a prospective nested case-control study.EBioMedicine · 2026Article
- The Great Potential of DNA Methylation in Triple-Negative Breast Cancer: From Biological Basics to Clinical Application.Biomedicines · 2026Review
- Aging-Related Mechanisms Underlying Carcinogenesis: Therapeutic Opportunities.Aging and disease · 2025Review
- Methylation-based biological age and cardiotoxicity risk in breast cancer patients treated with trastuzumab.Cardio-oncology (London, England) · 2025Article
- DNA methylation in breast cancer: early detection and biomarker discovery through current and emerging approaches.Journal of translational medicine · 2025Review
- Methylation Risk Score Modelling in Endometriosis: Evidence for Non-Genetic DNA Methylation Effects in a Case-Control Study.International journal of molecular sciences · 2025Article
- DNA methylation-predicted plasma protein levels and breast cancer risk.Breast cancer research : BCR · 2025Article
- Article
- Research on Prediction of Multiple Degenerative Diseases and Biomarker Screening Based on DNA Methylation.International journal of molecular sciences · 2025Article
- Pre-diagnosis blood DNA methylation profiling of twin pairs discordant for breast cancer points to the importance of environmental risk factors.Clinical epigenetics · 2024Article
- Machine learning unveils an immune-related DNA methylation profile in germline DNA from breast cancer patients.Clinical epigenetics · 2024Article
- Variance of age-specific log incidence decomposition (VALID): a unifying model of measured and unmeasured genetic and non-genetic risks.International journal of epidemiology · 2023Article
- Update Breast Cancer 2023 Part 1 - Early Stage Breast Cancer.Geburtshilfe und Frauenheilkunde · 2023Article
- Methylation-Based Biological Age and Hypertension Prevalence and Incidence.Hypertension (Dallas, Tex. : 1979) · 2023Article
- Using epigenomics to understand cellular responses to environmental influences in diseases.PLoS genetics · 2023Review
- Peripheral Immune Cell Composition is Altered in Women Before and After a Hypertension Diagnosis.Hypertension (Dallas, Tex. : 1979) · 2023Article
- Blood DNA methylation score predicts breast cancer risk: applying OPERA in molecular, environmental, genetic and analytic epidemiology.Molecular oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Although blood DNA methylation (DNAm) profiles are reported to be associated with breast cancer incidence, they have not been widely used in breast cancer risk assessment. Among a breast cancer case-cohort of 2774 women (1551 cases) in the Sister Study, we used candidate CpGs and DNAm estimators of physiologic characteristics to derive a methylation-based breast cancer risk score, mBCRS. Overall, 19 CpGs and five DNAm estimators were selected using elastic net regularization to comprise mBCRS. In a test set, higher mBCRS was positively associated with breast cancer incidence, showing similar strength to the polygenic risk score (PRS) based on 313 single nucleotide polymorphisms (313 SNPs). Area under the curve for breast cancer prediction was 0.60 for self-reported risk factors (RFs), 0.63 for PRS, and 0.63 for mBCRS. Adding mBCRS to PRS and RFs improved breast cancer prediction from 0.66 to 0.71. mBCRS findings were replicated in a nested case-control study within the EPIC-Italy cohort. These results suggest that mBCRS, a risk score derived using blood DNAm, can be used to enhance breast cancer prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.